A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Condition: Breast Cancer, Early Breast Cancer Interventions: Drug: Camizestrant; Drug: Tamoxifen; Drug: Anastrozole; Drug: Letrozole; Drug: Exemestane Sponsor: AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Arimidex | AstraZeneca | Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | HER2 | Research | Study | Tamoxifen